These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Digitalis--selected problems and controversies].
    Author: Nartowicz E, Paczkowska B.
    Journal: Wiad Lek; ; 42(19-21):1080-5. PubMed ID: 2638057.
    Abstract:
    Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis. There is no consensus of opinions of the effectiveness of digitalis treatment in cases of cardiac failure which is due to lack of uniformity of qualification of patients for studies and absence of accepted universally haemodynamic parameters of the effectiveness of the positive inotropic action of these glycosides. The usefulness of these glycosides in patients with cardiac failure and paroxysmal or stable atrial fibrillation and ventricular tachycardia is unquestionable. Digitalis is effective in the treatment of mild cardiac failure, but is ineffective in its IV stage (NYHA). There is still a controversy on the use of digitalis glycosides in acute myocardial infarction with associated myocardial failure. In acute myocardial infarction digitalis glycosided should not be used, with the exception of cases with coexistent supraventricular arrhythmia and ventricular tachycardia. It is still difficult to establish unequivocally the effect of digitalization of patients after acute phase of myocardial infarction and after discharge from hospital on further survival. The future place of digitalis glycosides in the treatment of cardiac failure will depend on the results of studies comparing them with new positive inotropic drugs. The place of digitalis glycosides in the treatment of haemodynamic cousegnences of mitral stenosis, but they are useful in supraventricular arrhythmias during mitral stenosis, and for alleviation of right-ventricular cardiac failure.
    [Abstract] [Full Text] [Related] [New Search]